DoD Peer Reviewed Medical, Clinical Trial Award
ID: 353207Type: Posted
Overview

Buyer

Dept. of the Army -- USAMRAA (DOD-AMRAA)

Eligible Applicants

Unrestricted

Funding Category

Science and Technology and other Research and Development

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/353207
Timeline
  1. 1
    Forecast Posted Not available
  2. 2
    Forecast Due Not available
  3. 3
    Posted Mar 26, 2024, 12:00 AM UTC
  4. 4
    Due Aug 19, 2024, 12:00 AM UTC
Description

The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering the FY24 Peer Reviewed Medical Clinical Trial Award, aimed at advancing medical research pertinent to military health. This grant supports the rapid implementation of clinical trials that evaluate promising interventions for various health issues affecting service members, veterans, and their families, with a focus on specific congressionally directed topics such as autoimmune disorders and infectious diseases. The program anticipates funding approximately 12 awards with a total estimated budget of $90 million, allowing for trial budgets up to $500,000 for planning phases and unrestricted for full trials, with key deadlines including pre-applications due by May 13, 2024, and full applications by August 19, 2024. For further inquiries, applicants can contact the CDMRP Help Desk at help@eBRAP.org or call 301-682-5507.

Point(s) of Contact
help@eBRAP.org
Files
Title
Posted
HT942524PRMRPCTA-GG.pdf
Aug 24, 2024, 2:22 AM UTC
The Department of Defense (DOD) has announced the FY24 Peer Reviewed Medical Clinical Trial Award, part of the Defense Health Program, aimed at advancing medical research directly relevant to military health. The announcement outlines critical deadlines for application submissions, with pre-applications due by May 13, 2024, and full applications by August 19, 2024. This program targets specific congressionally directed FY24 topics to improve healthcare for service members, veterans, and their families, highlighting areas such as autoimmune disorders, cardiovascular health, and infectious diseases. Eligible applicants include various organizations, and the primary goal is to implement clinical trials that evaluate promising interventions related to diverse health issues. Applications must align with one or more defined strategic goals and demonstrate significant potential impacts on military health. There are two submission categories based on study stages: Clinical Trial with Planning Phase and Clinical Trial Only. Each application must provide preliminary data, demonstrate access to patient populations, and detail study design, statistical analysis plans, and collaboration efforts within military and academic settings. Funding will support trials with a budget of up to $500,000 for the planning phase, with the overall budget for trials unrestricted, contingent on project relevance and merit. The DOD anticipates allocating approximately $90 million to fund approximately 12 awards, focused on improving health outcomes for service members and leveraging military-specific research capabilities.
Similar Opportunities
BROAD AGENCY ANNOUNCEMENT (BAA) for Extramural Biomedical and Human Performance Research and Development Department of Defense
Dept. of the Army -- USAMRAA
The Department of the Army, through the US Army Medical Research Acquisition Activity (USAMRAA), has announced a Broad Agency Announcement (BAA) for Extramural Biomedical and Human Performance Research and Development. This opportunity invites unrestricted applicants to submit proposals aimed at advancing biomedical research and development, with a focus on enhancing human performance. The program is critical for fostering innovation in science and technology, particularly in areas that support the Department of Defense's mission. The estimated total program funding is $10 million, with individual awards ranging from $750,000 to $50 million, and proposals are due by July 31, 2028. For further inquiries, applicants can contact the CDMRP Help Desk at help@eBRAP.org or by phone at 301-682-5507.
Airman Readiness Medical Research (ARMR) Hybrid BAA
Air Force -- Research Lab
The Air Force Research Laboratory (AFRL) is soliciting proposals for the Airman Readiness Medical Research (ARMR) program through a Hybrid Broad Agency Announcement (BAA) designated FA8650-20-S-6008. The primary objectives of this initiative are to conduct medical research aimed at optimizing the health and performance of Airmen, focusing on ensuring medical availability and understanding the effects of various operational environments on Airman well-being. This program is critical for enhancing the operational readiness of military personnel, particularly in high-demand mission scenarios, with key research areas including aeromedical evacuation, cognitive performance, and exposure health. The total funding available for this program is estimated at $480 million, with individual awards ranging from $50,000 to $49 million. Interested parties are encouraged to submit white papers by May 1, 2025, and can direct inquiries to Amber A. Taylor at amber.taylor.9@us.af.mil.
Fiscal Year (FY) 2026 Department of Defense Multidisciplinary Research Program of the University Research Initiative (MURI) Department of Defense Army
Dept of the Army -- Materiel Command
The Department of the Army's Materiel Command is offering a funding opportunity through the Fiscal Year 2026 Multidisciplinary Research Program of the University Research Initiative (MURI), aimed at fostering innovative research with military applications. This program invites proposals exclusively from U.S. institutions of higher education, including universities with degree-granting programs in science and engineering, to conduct high-risk basic research that addresses significant scientific challenges. With an estimated total program funding of $170 million over five years, the MURI program will support annual grants of up to $1.5 million, with proposals due by September 5, 2025, and optional white papers due by May 2, 2025. Interested applicants can reach out to Dr. Sue Kase at usarmy.rtp.devcom-arl.mbx.aro-muri@army.mil for further information.
Military and Civilian Partnership for Trauma Readiness Grant Program/Mission Zero
Admin for Strategic Preparedness and Response
The Administration for Strategic Preparedness and Response is offering the Military and Civilian Partnership for Trauma Readiness Grant Program, also known as the Mission Zero Act, to support high-acuity trauma centers in enhancing military-civilian partnerships for improved trauma care. This grant program aims to award up to 30 eligible trauma centers, enabling military trauma teams to provide full-time trauma and acute care services, thereby strengthening the nation's response to public health and medical emergencies. With an estimated total program funding of $4 million and an award ceiling of $4 million per grant, interested applicants, including nonprofits without 501(c)(3) status and hospitals, should note that the application period is expected to open on January 15, 2025, with a closing date of April 14, 2025. For further inquiries, applicants can contact Leslie Beck at 301-346-4857 or via email at leslie.beck@hhs.gov.
Tactical Behaviors for Autonomous Maneuver
Dept of the Army -- Materiel Command
The Department of the Army's Materiel Command is offering a funding opportunity through the Tactical Behaviors for Autonomous Maneuver Collaborative Research Program (TBAM-CRP) aimed at enhancing the capabilities of robotic and autonomous systems (RAS) for military operations in complex environments. This program seeks proposals that develop coordinated and adaptive behaviors for small groups of autonomous agents, focusing on innovative maneuver tactics and strategies to operate effectively in multi-domain operations against peer adversaries. The TBAM-CRP is critical for advancing military capabilities, leveraging new technologies in robotics and autonomous systems to improve situational awareness and operational effectiveness on the battlefield. Interested applicants, including institutions of higher education and for-profit organizations, are invited to submit proposals by April 24, 2024, with funding amounts ranging from $100,000 to $2.3 million available per award. For further inquiries, applicants can contact Christopher D. Justice at usarmy.adelphi.devcom-arl.mbx.tbam-crp-questions@army.mil.
Department of Defense HIV/AIDS Prevention Program
Dept. of the Army -- USAMRAA
The Department of the Army, through the US Army Medical Research and Materiel Command (USAMRAA), is offering a federal grant opportunity titled the Department of Defense HIV/AIDS Prevention Program (DHAPP). This program aims to save lives and prevent HIV infections by supporting the development of interventions and programs within military health systems, particularly in foreign countries, to achieve HIV/AIDS epidemic control. The DHAPP focuses on enhancing military capacity for ownership and behavioral change, aligning with national strategies, and ensuring sustainable HIV prevention and treatment services. Interested applicants can reach out to Ebony Simmons at ebony.s.simmons.civ@health.mil or by phone at 301-619-2105 for further information. The application deadline is September 18, 2027, with an expected seven awards to be made under this cooperative agreement, which does not require cost sharing or matching.
NFRP Outreach and Invitation for Response
Dept. of the Army -- USAMRAA
The Department of the Army, through the US Army Medical Research Acquisition Activity (USAMRAA), is forecasting an opportunity for a Research-based Other Transactions Agreement (rOTA) under the Neurofibromatosis Research Program (NFRP). This initiative aims to accelerate the clinical translation of basic research related to neurofibromatosis (NF) by conducting collaborative Phase I and II clinical trials focused on promising therapeutic agents for NF1, NF2, and schwannomatosis. Historically, this requirement has been addressed through assistance agreements, and the government is now seeking feedback on this proposed approach, emphasizing the need for cost-sharing arrangements and access to patient populations. Interested parties can direct inquiries to Jason D. Kuhns at jason.d.kuhns.civ@mail.mil, with the opportunity being part of the FY21 portfolio and requiring a demonstrated history of collaborative research among participants.
NIAID SBIR Phase II Clinical Trial Implementation Cooperative Agreement (U44 Clinical Trial Required)
National Institutes of Health
The National Institutes of Health (NIH) is offering a funding opportunity through the NIAID SBIR Phase II Clinical Trial Implementation Cooperative Agreement (FON PAR-24-099) aimed at small business concerns proposing investigator-initiated clinical trials that align with the NIAID's research mission. This program supports hypothesis-driven and milestone-driven clinical trials, particularly those classified as high-risk, which may involve unique interventions or the use of licensed products for unapproved indications. The initiative underscores the government's commitment to advancing innovative clinical research to address significant healthcare challenges, with funding of up to $1 million annually available for meritorious applications. Interested applicants must adhere to strict guidelines and submit their applications by the various deadlines, with the first due date on April 12, 2024, and the final deadline on January 13, 2027. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
NIAMS Clinical Trial Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required)
National Institutes of Health
The National Institutes of Health (NIH), through the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), is offering a funding opportunity for the implementation of interventional clinical trials via the Clinical Trial Implementation Cooperative Agreement (UG3/UH3). This initiative aims to support investigation-driven projects for both single and multi-site trials across all phases, emphasizing the importance of preliminary planning and the completion of necessary approvals before trial execution. The funding opportunity reflects NIAMS' commitment to advancing research in arthritis and musculoskeletal diseases, with grants of up to $250,000 available for the UG3 phase and no specific limit for UH3 project budgets, designed for up to six years of support. Interested applicants can find more information and application details at the provided link, with the application deadline set for March 4, 2027.
NIAMS Clinical Trial Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required)
National Institutes of Health
The National Institutes of Health (NIH) has announced a funding opportunity for the NIAMS Clinical Trial Implementation Cooperative Agreement (UG3/UH3), aimed at supporting interventional clinical trials focused on rheumatic, musculoskeletal, and skin diseases. This initiative encompasses a two-phase approach, where the UG3 phase involves trial preparation and the UH3 phase focuses on trial execution, contingent upon meeting specific milestones. The program emphasizes the importance of developing clinical protocols, obtaining IRB approval, and securing necessary resources, while also promoting health equity by engaging individuals with lived experience in the research process. Interested applicants can apply for funding up to $250,000 for the UG3 phase, with a closing date for submissions set for March 4, 2027. For further inquiries, applicants may contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-24-208.html.